Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extension of phase II therapeutic trial with a humanized non-mitogenic CD3 (ChAgly CD3) [otelixizumab] monoclonal antibody in recently diagnosed type 1 diabetic patients

Next Previous
Trial Profile

Extension of phase II therapeutic trial with a humanized non-mitogenic CD3 (ChAgly CD3) [otelixizumab] monoclonal antibody in recently diagnosed type 1 diabetic patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Otelixizumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 01 Nov 2023 Results reanalyzing trial data to compare the ability of baseline acutely glucose-stimulated proinsulin, C-peptide and PI/CP to predict functional outcome, published in the Diabetes Research and Clinical Practice
  • 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
  • 20 Mar 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top